Chemclin Diagnostics Co LtdSHG 688468 Stock Report

Chemclin Diagnostics Co., Ltd. engages in the research, development, production, and sales of vitro diagnostic reagents and instruments for clinical immuno chemiluminescence diagnosis in China. The company is headquartered in Beijing, Beijing and currently employs 632 full-time employees. The company went IPO on 2021-04-09. The firm's products are LiCA series of diagnostic reagents based on light-induced chemiluminescence and Chemclin series of diagnostic reagents and instruments based on enzymatic chemiluminescence, which are mainly used in infectious diseases (such as hepatitis B, hepatitis C, Acquired Immunodeficiency Syndrome, syphilis, hepatitis A, hepatitis E) Detection of markers, tumor markers, thyroid hormones, reproductive endocrine hormones, diabetes, myocardial markers and inflammation. The firm distributes its products and services within the domestic market.